Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00540514 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00540514
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00540514 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase III Trial of ABI-007 and Carboplatin Compared With Taxol and Carboplatin as First-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2007
Completion date
February 1, 2013
Enrollment
1,052 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung carcinoma